Liliana Elena Weimer | Medicine and Health Sciences | Best Researcher Award

Published on by Top Teachers

Best Researcher Award

Liliana Elena Weimer
Italian National Institute of Health, Italy
Liliana Elena Weimer
Affiliation Italian National Institute of Health
Country Italy
Google Scholar 2q3g0CAAAAAJ
Documents 128
Citations 2,534
h-index 22
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
Scopus ID 6701388312
ORCID 0000-0002-1554-3150

Liliana Elena Weimer is a medical doctor and clinical researcher with over 30 years of experience in infectious diseases, clinical trials, and global health. Since 2022 she serves as First Researcher (Level II) at the Center for Global Health – Istituto Superiore di Sanità (ISS), Rome, Italy. Her career spans landmark HIV/HCV studies, COVID‑19 surveillance, Long‑COVID coordination, and international collaborations with WHO, the G20, and the American Clinical Trials Group.[1][2]

She has participated in national and multinational cohort studies, public health surveillance programs, and clinical research initiatives focused on infectious diseases and global health. As of September 2026, she has authored or co-authored more than 177 scientific publications and has contributed to research programs involving the American Clinical Trials Group, European collaborative projects, WHO-related activities, and Italian national surveillance systems. Her scholarly profile reflects sustained engagement in evidence-based medicine, public health research, and clinical investigation across several decades.[1][2]

Abstract

This article presents the academic and research profile of Dr. Liliana Elena Weimer, nominated for the Best Researcher Award in recognition of her outstanding contributions to clinical virology, public health surveillance, and international collaborative research. With a career spanning more than three decades at the Italian National Institute of Health (ISS), Dr. Weimer has coordinated national and multinational trials on HIV and HCV, contributed to the PITER cohort (25,000 patients), and led COVID‑19 and Long‑COVID surveillance protocols. Her work is characterised by high‑impact publications, a consistent h‑index of 22, and active engagement in European projects (ORCHESTRA, PREVENT Horizon, SHIELD). The nomination is supported by her record of public competition successes, teaching, and service with Doctors Without Borders.[1]

Keywords

Best Researcher Award, HIV/HCV clinical trials, PITER cohort, COVID‑19 surveillance, Long‑COVID, Malattie Infettive Long Covid, Doctor in Medicine, Infectious Diseases.

Introduction

The Best Researcher Award recognises individuals who demonstrate exceptional scientific output, leadership, and translational impact. Liliana Elena Weimer, MD, has built a distinguished career at the Istituto Superiore di Sanità (ISS), where she has been instrumental in shaping infectious disease research in Italy and beyond. Her work encompasses antiretroviral therapy optimisation, hepatitis C elimination strategies, and the establishment of national surveillance systems for HIV, HCV, and SARS‑CoV‑2. Notably, she is a member of the ISS COVID‑19 National Surveillance Group and the PITER study coordination team, and she contributes to WHO guidelines on Long‑Covid. Her international collaborations and sustained publication record make her a strong candidate for this award.[3]

Research Profile

Dr. Liliana Elena Weimer holds a medical degree from the University of Buenos Aires and a second MD from the University of L’Aquila, with specialisations in Infectious Diseases and Clinical Pharmacology. She has been a researcher at ISS since 1990, winning public competitions for fixed‑term, permanent, and First Researcher positions. Her research profile is characterised by a strong commitment to clinical epidemiology and trial methodology. She has contributed to landmark studies such as ACTG 384/388 (Italy‑USA AIDS trials), the PITER HCV cohort, and the European ORCHESTRA project. She also coordinates the national Long‑COVID surveillance protocol (2021‑2026) funded by the Italian Ministry of Health. With over 128 documents, 2,534 citations, and an h‑index of 22 (Scopus), she maintains a visible presence in the field.[2][4]

  • Senior Clinical Researcher at the Italian National Institute of Health (ISS), Rome.
  • More than three decades of experience in multicenter clinical trials and epidemiological research.
  • Collaborator with international HIV and HCV research networks.
  • Contributor to national SARS-CoV-2 and Long COVID surveillance programs.
  • Participant in European collaborative projects including ORCHESTRA, PREVENT Horizon, SHIELD, EURO-PERISTAT, and JA-05.
  • Member of professional organizations focused on infectious diseases and public health.

Research Contributions

Dr. Liliana Elena Weimer’s contributions are organised around three pillars: clinical trials and cohort studies, public health surveillance, and global health collaborations. She has coordinated over twenty national and international multicentre trials, including the Italian Protease Inhibitors Registry and the NIA surveillance network. As part of the PITER study, she contributed to the largest Italian HCV cohort (25,000 patients), informing treatment strategies for cirrhosis and hepatocellular carcinoma. During the COVID‑19 pandemic, she joined the ISS national surveillance group and collaborated with Bambino Gesù Pediatric Hospital, providing clinical and epidemiological support. She also serves as an external consultant for WHO’s Long‑Covid guidelines and is a member of the Brussels Network of Expertise on Long‑Covid.[5]

Liliana Elena Weimer’s research portfolio encompasses HIV treatment optimization, hepatitis C management, SARS-CoV-2 surveillance, and Long COVID characterization. Her participation in national cohort studies and international clinical trials has contributed to understanding treatment effectiveness, patient outcomes, and disease epidemiology.[1][3]

  • Clinical trials and cohort studies involving HIV therapies.
  • Research on HCV treatment outcomes and long-term virological response.
  • Investigation of monoclonal antibody strategies against emerging SARS-CoV-2 variants.
  • Long COVID symptom characterization and longitudinal follow-up studies.
  • Public health surveillance and antimicrobial resistance research.
  • Support for healthcare access initiatives in resource-limited settings.

Publications

Dr. Liliana Elena Weimer has authored or co‑authored more than 120 peer‑reviewed articles, book chapters, and monographs. Her work appears in high‑impact journals including Hepatology, Children, and Journal of Pediatrics Research Reviews. She received the Best Research Award from the journal Children (IF 2.5) for a study on the clinical characterisation of adolescents with Long‑COVID. She has also published two books on post‑COVID sequelae and SARS‑CoV‑2 variants. Below is a selection of her most cited works:

  • Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, … Weimer LE (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3):833‑844.
  • George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, … Weimer LE (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3):729‑738.
  • Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, … Weimer LE (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3):715‑725.

Research Impact

With over 2,534 citations and an h‑index of 22, Dr. Liliana Elena Weimer’s work has shaped clinical practice in hepatitis C and HIV care. Her studies on sustained virologic response and long‑term outcomes after HCV therapy are frequently cited in guidelines. She has received multiple recognitions, including an Abstract of Distinction at the AASLD Liver Meeting (2018) and the 2025 Best Research Award from Children journal. She was a Special Invitee to the G20 Health Summit 2023 and serves as a lay judge at the Court of Assizes in Rome. Her impact extends beyond academia: she is a volunteer with Doctors Without Borders (since 1992), providing AIDS therapies in Brazil, and actively participates in public health emergency responses.[1][3]

Award Suitability

The Best Researcher Award recognises sustained excellence, and Dr. Liliana Elena Weimer’s trajectory exemplifies this. She has won three public competitions at the ISS (fixed‑term, permanent, and First Researcher), demonstrating peer‑reviewed career progression. She coordinates the national PITER HCV cohort and the Long‑COVID surveillance protocol, and she has contributed to WHO guidelines. Her publication record includes landmark articles in hepatology, and she has received journal‑level awards for her work on Long‑COVID. Her international collaborations with the American Clinical Trials Group, INSERM, and the European Commission place her among the leading clinical researchers in Italy. This award would further acknowledge her role in translating research into public health action.[4]

Conclusion

Dr. Liliana Elena Weimer is a medical researcher of high calibre, with a career that bridges clinical trials, epidemiological surveillance, and global health equity. Her work on HIV, HCV, and COVID‑19 has informed national and international guidelines, and her commitment to service—through Doctors Without Borders and public health emergencies—distinguishes her as a compassionate and effective leader. The data presented—128 documents, 2,534 citations, h‑index 22, and consistent recognition—support her nomination for the Best Researcher Award. Her profile aligns with the core values of the award: scientific rigor, translational impact, and dedication to improving human health.[5]

References

  1. Scopus. (n.d.). Author details: Weimer, Liliana Elena, Author ID 6701388312. Scopus Preview.https://www.scopus.com/pages/authors/6701388312
  2. Google Scholar. (n.d.). Liliana Elena Weimer – citations & h‑index. Google Scholar.https://scholar.google.co.uk/citations?user=2q3g0CAAAAAJ
  3. Morgan, T. R., Ghany, M. G., Kim, H. Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., … & Weimer, L. E. (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3), 833‑844. https://doi.org/10.1002/hep.23744
  4. George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J., … & Weimer, L. E. (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3), 729‑738. https://doi.org/10.1002/hep.22694
  5. Saxena, V., Nyberg, L., Pauly, M., Dasgupta, A., Nyberg, A., Piasecki, B., … & Weimer, L. E. (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3), 715‑725. https://doi.org/10.1002/hep.27922

Timea Claudia Ghitea | Medicine and Health Sciences | Women Researcher Award

Published on by Top Teachers

Women Researcher Award

Timea Claudia Ghitea
University of Oradea, Romania
Timea Claudia Ghitea
Affiliation University of Oradea
Country Romania
Scopus ID 57214826600
Documents 103
Citations 722
h-index 15
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
ORCID 0000-0001-8981-1958
Google Scholar VsFBqbQAAAAJ

Timea Claudia Ghitea is a Romanian academic, pharmacist, nutrition specialist, and university educator affiliated with the Faculty of Medicine and Pharmacy at the University of Oradea. Her scholarly activities integrate clinical nutrition, metabolic disorders, dietetics, rehabilitation medicine, pharmaceutical sciences, and public health research. Through academic teaching, clinical practice, and scientific publication, she has contributed to advancing evidence-based nutritional interventions and multidisciplinary healthcare approaches. Her research profile demonstrates sustained engagement in metabolic syndrome, diabetes, probiotics, sarcopenia, rehabilitation outcomes, and maternal health studies.[1][2]

Abstract

This article summarizes the academic achievements, professional experience, research output, and scientific impact of Timea Claudia Ghitea. Her work spans medicine, pharmacy, nutrition science, and metabolic health, with particular emphasis on evidence-based dietary interventions and patient-centered healthcare. Through extensive publication activity and interdisciplinary collaboration, she has contributed to contemporary understanding of chronic disease management, rehabilitation nutrition, and probiotic-based therapeutic approaches.[1]

Keywords

Clinical Nutrition, Dietetics, Metabolic Syndrome, Diabetes Mellitus, Probiotics, Sarcopenia, Rehabilitation Medicine, Pharmacy, Biomedical Sciences, Public Health, Farmacie, Nutriție, Stiinte Biomedicale, Microbiommi, Microbiologie, General & Internal Medicine, Research & Experimental Medicine, Biochemistry & Molecular Biology, Health Care Sciences & Services, Nutrition & Dietetics.

Introduction

Timea Claudia Ghitea has developed a multidisciplinary career combining pharmaceutical practice, academic instruction, nutrition consultancy, and biomedical research. Since 2017 she has served as University Assistant at the Faculty of Medicine and Pharmacy, University of Oradea, while simultaneously practicing as a clinical and sports nutritionist. Her educational background includes degrees in biology, chemistry, pharmacy, cell biology, and a PhD in Biomedical Sciences with specialization in clinical and sports nutrition, providing a comprehensive foundation for translational healthcare research.[1]

Research Profile

The research profile of Timea Claudia Ghitea reflects sustained scholarly productivity in medicine and health sciences, supported by more than one hundred indexed publications, substantial citation activity, and an established h-index. Her investigations focus on nutrition-related interventions, metabolic disorders, gastrointestinal microbiota, pharmaceutical sciences, rehabilitation outcomes, and clinical management strategies for chronic diseases. The interdisciplinary nature of her work facilitates collaboration among physicians, pharmacists, nutritionists, and public health researchers.[1][2]

Research Contributions

  • Advanced understanding of probiotic and prebiotic applications in metabolic syndrome and type 2 diabetes management.[3]
  • Contributed to evidence regarding nutritional therapy for sarcopenia associated with immobilization and chronic disease conditions.[6]
  • Investigated dietary intervention strategies influencing sarcopenic indicators among patients with metabolic syndrome.[7]
  • Supported multidisciplinary studies examining rehabilitation outcomes and prevention of secondary complications following spinal cord injury.[5]
  • Participated in comprehensive reviews addressing maternal health and antiphospholipid syndrome during pregnancy.[4]

Publications

Notable publications include research on gut microbiota and metabolic disease, pregnancy-related autoimmune disorders, rehabilitation medicine, nutrition-based interventions for sarcopenia, and metabolic syndrome management. These studies collectively demonstrate a commitment to translational healthcare research with practical clinical applications.[3][4][5][6][7]

  1. Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium.
  2. Antiphospholipid Syndrome in Pregnancy: A Comprehensive Literature Review.
  3. The Outcomes of Robotic Rehabilitation Assisted Devices Following Spinal Cord Injury and the Prevention of Secondary Associated Complications.
  4. The Contribution of Diet Therapy and Probiotics in the Treatment of Sarcopenia Induced by Prolonged Immobilization Caused by the COVID-19 Pandemic.
  5. The Influence of Diet Therapeutic Intervention on the Sarcopenic Index of Patients with Metabolic Syndrome.

Research Impact

With 103 indexed documents, 722 citations, and an h-index of 15, Timea Claudia Ghitea has established a measurable academic presence within medicine and health sciences. Her publications have contributed to contemporary discussions regarding nutrition-based therapeutic approaches, metabolic disease management, rehabilitation medicine, and clinical healthcare optimization. The citation performance of her work indicates ongoing scholarly engagement and relevance within multiple biomedical disciplines.[1]

Award Suitability

Timea Claudia Ghitea demonstrates several characteristics commonly associated with recognition through a Women Researcher Award. These include sustained publication productivity, interdisciplinary scientific contributions, active involvement in academic teaching, leadership in healthcare practice, mentorship activities, professional society memberships, and research addressing significant public health challenges. Her integration of clinical practice and academic scholarship illustrates a model of translational research with practical societal relevance.[1][2]

Conclusion

Timea Claudia Ghitea has built a distinguished academic and professional career spanning pharmacy, nutrition, medicine, and health sciences. Her research contributions, publication record, educational achievements, and clinical expertise collectively demonstrate a sustained commitment to advancing evidence-based healthcare. These accomplishments support her profile as a noteworthy contributor to biomedical research and higher education.

References

  1. Elsevier. (n.d.). Scopus author details: Timea Claudia Ghitea, Author ID 57214826600. Scopus. https://www.scopus.com/authid/detail.uri?authorId=57214826600
  2. ORCID. (n.d.). Timea Claudia Ghitea researcher profile. https://orcid.org/0000-0001-8981-1958
  3. TC Ghitea et al. Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium. Microorganisms. https://doi.org/10.3390/microorganisms9030618
  4. TC Ghitea et al. Antiphospholipid Syndrome in Pregnancy: A Comprehensive Literature Review. BMC Pregnancy and Childbirth. https://link.springer.com/article/10.1186/s12884-025-07471-w
  5. TC Ghitea et al. The Outcomes of Robotic Rehabilitation Assisted Devices Following Spinal Cord Injury and the Prevention of Secondary Associated Complications. Medicina. https://doi.org/10.3390/medicina58101447
  6. TC Ghitea et al. The Contribution of Diet Therapy and Probiotics in the Treatment of Sarcopenia Induced by Prolonged Immobilization Caused by the COVID-19 Pandemic. Nutrients. https://doi.org/10.3390/nu14214701
  7. Ghitea TC et al. The influence of diet therapeutic intervention on the sarcopenic index of patients with metabolic syndrome. Acta Endocrinologica. https://pmc.ncbi.nlm.nih.gov/articles/PMC8126402/

Ömer Yavuz | Medicine and Health Sciences | Excellence in Research Award

Published on by Top Teachers

Excellence in Research Award

Ömer Yavuz
Başakşehir Çam and Sakura City Hospital, Turkey
Ömer Yavuz
Affiliation Başakşehir Çam and Sakura City Hospital
Country Turkey
Scopus ID 56712503200
Documents 11
Citations 44
h-index 4
Subject Area Medicine and Health Sciences
Event Top Teachers Awards

Ömer Yavuz is a thoracic surgery specialist affiliated with Başakşehir Çam and Sakura City Hospital. He has contributed significantly to thoracic surgery research through clinical investigations, minimally invasive surgical innovations, oncological studies, and multidisciplinary collaborations.[1] His academic profile reflects active participation in peer-reviewed publications, international scientific congresses, educational activities, and collaborative healthcare research initiatives within thoracic and pulmonary medicine. The Excellence in Research Award recognizes his distinguished scholarly achievement, sustained scientific contribution, and professional advancement in the field of medicine and health sciences.[2]

Abstract

Ömer Yavuz is a Turkish thoracic surgery specialist whose academic activities encompass clinical thoracic surgery, pulmonary oncology, minimally invasive surgical procedures, robotic thoracic surgery, and perioperative patient management. His scholarly contributions include peer-reviewed journal publications, conference presentations, collaborative multicenter studies, and educational involvement in thoracic surgery seminars.[3] His research portfolio demonstrates continuing engagement with contemporary surgical techniques and evidence-based clinical practice, particularly in lung cancer surgery, thoracic oncology, port catheter applications, and minimally invasive approaches.[4]

Keywords

Thoracic Surgery, Lung Cancer, Robotic Surgery, Pulmonary Oncology, Minimally Invasive Surgery, Thoracic Oncology, Video-Assisted Thoracoscopic Surgery, Surgical Research, Medical Education, Clinical Research.

Introduction

Thoracic surgery remains an essential subspecialty within medicine, requiring the integration of surgical precision, oncological knowledge, and multidisciplinary clinical coordination. Research in this field contributes to the advancement of minimally invasive interventions, perioperative management, and improved long-term patient outcomes. Within this context, Ömer Yavuz has participated in clinical and academic activities addressing thoracic surgical practice, lung cancer management, robotic-assisted procedures, and rare thoracic disorders.[5]

His professional training includes medical education at Gülhane Military Medical Faculty and specialization in thoracic surgery at Gülhane Military Medical Academy Haydarpaşa Training Hospital. Subsequent clinical appointments at Muş State Hospital, Koç University Hospital, and Başakşehir Çam and Sakura City Hospital contributed to the development of his clinical and academic profile.[6]

Research Profile

The research profile of Ömer Yavuz reflects interdisciplinary collaboration across thoracic surgery, oncology, pathology, and minimally invasive surgical technologies. His publications include clinical analyses, surgical case reports, retrospective investigations, translational research studies, and conference proceedings focused on thoracic diseases and operative outcomes.[7]

Research topics addressed in his work include pectus excavatum surgery, pleurodesis techniques, thoracic oncology, spread through air spaces in lung adenocarcinoma, immune profiling after minimally invasive lobectomy, robotic thoracic surgery, port catheter complications, and bibliometric analyses of surgical literature.[8]

In addition to publication activities, he has participated in national and international scientific congresses, including presentations associated with the World Conference on Lung Cancer, the European Society of Thoracic Surgeons, and Turkish thoracic surgery congresses.[9]

Research Contributions

Ömer Yavuz has contributed to research evaluating minimally invasive surgical procedures and thoracic oncological management. His collaborative study on immune profiling after minimally invasive lobectomy examined postoperative immunological responses following thoracic surgical intervention.[10]

Additional research contributions include investigations into thoracic surgical outcomes during the COVID-19 pandemic, demonstrating the feasibility of elective cancer surgery during periods of healthcare system restriction.[11] Other studies addressed prognostic indicators in lung adenocarcinoma, including spread through air spaces identified through PET/CT imaging modalities.[12]

His more recent research activities involve robotic-assisted thoracic surgery, landmark-based port catheter placement techniques, thoracic outlet syndrome procedures, and perioperative management strategies in low-resource surgical settings.[13] Several accepted publications scheduled for 2026 further demonstrate ongoing academic engagement in thoracic surgical innovation and healthcare research productivity.[14]

  • Research in minimally invasive thoracic surgery and robotic-assisted procedures.
  • Clinical investigations in lung cancer surgery and thoracic oncology.
  • Studies involving perioperative outcomes and surgical feasibility during the COVID-19 pandemic.
  • Development of port catheter placement approaches in resource-limited clinical settings.
  • Participation in multidisciplinary and international thoracic surgery collaborations.

Publications

Ömer Yavuz has contributed to thoracic surgery research through publications focused on minimally invasive surgery, thoracic oncology, robotic-assisted procedures, perioperative management, and pulmonary diseases. His scholarly work includes clinical investigations on lung adenocarcinoma, immune profiling after lobectomy, pleurodesis techniques, hyperhidrosis surgery outcomes, and port catheter complications. He has also participated in multidisciplinary and international collaborative studies published in peer-reviewed medical journals, including research related to COVID-19 surgical management and malignant pleural mesothelioma. These publications demonstrate sustained engagement with evidence-based thoracic surgery, innovative surgical methodologies, and contemporary clinical challenges within medicine and health sciences.

Research Impact

The academic contributions of Ömer Yavuz have supported ongoing discussions related to thoracic surgical techniques, perioperative care, robotic-assisted interventions, and oncological thoracic procedures. His Scopus-indexed publication record demonstrates measurable citation activity and participation in collaborative scientific research.[15]

His involvement in educational seminars and professional associations, including the Turkish Thoracic Society, Turkish Society of Thoracic Surgery, and European Society of Thoracic Surgeons, further reflects sustained engagement with academic medicine and surgical education.[16]

  • Peer-reviewed publications indexed in international academic databases.
  • Conference presentations at national and international thoracic surgery congresses.
  • Research participation in EU Framework Program and TÜBİTAK-supported scientific projects.
  • Ongoing publication activity in robotic thoracic surgery and surgical innovation.
  • Academic teaching contributions within thoracic surgery clinical seminars.

Award Suitability

The scholarly record of Ömer Yavuz demonstrates alignment with the objectives of the Excellence in Research Award presented through the Top Teachers Awards platform. His contributions to thoracic surgery research, publication activity in peer-reviewed journals, participation in international congresses, and involvement in educational and collaborative medical initiatives collectively support recognition for academic and professional achievement.[17]

Particular areas of distinction include minimally invasive thoracic surgery, robotic-assisted surgical techniques, thoracic oncology research, and clinical studies concerning perioperative outcomes and surgical methodologies in varying healthcare settings.[18]

Conclusion

Ömer Yavuz has established an academic and clinical profile characterized by ongoing participation in thoracic surgery research, scientific collaboration, and surgical education. His publication history, conference involvement, and clinical specialization reflect continued engagement with evidence-based thoracic surgical practice and medical research development. The breadth of his scholarly contributions within medicine and health sciences provides a substantial basis for recognition through the Excellence in Research Award.[19]

References

    1. Elsevier. (n.d.). Scopus author details: Ömer Yavuz, Author ID 56712503200. Scopus. https://www.scopus.com/authid/detail.uri?authorId=56712503200
    2. Başakşehir Çam and Sakura City Hospital. (n.d.). Thoracic surgery and clinical research activities.
    3. Yıldızhan, A., Candaş, F. H., Yavuz, Ö., et al. (2015). Experiences with the Nuss Procedure in Young Adult Patients with Pectus Excavatum.DOI: https://doi.org/10.5606/tgkdc.dergisi.2015.10497
    4. Erus, S., Öztürk, A. B., Albayrak, Ö., et al. (2021). Immune Profiling After Minimally Invasive Lobectomy. DOI: https://doi.org/10.1093/icvts/ivaa296
    5. Marazioti, A., et al. (2021). KRAS Signaling in Malignant Pleural Mesothelioma. DOI: https://doi.org/10.15252/emmm.202013631
    6. Curriculum Vitae of Ömer Yavuz. (2026). Professional experience and academic background.
    7. Süer, H., et al. (2023). Combination of CEACAM5, EpCAM and CK19 Gene Expressions in Mediastinal Lymph Node Micrometastasis. DOI: https://doi.org/10.1186/s13019-023-02297-z
    8. Yavuz, Ö., İşcan, M. (2025). Port Catheter Thickness and Its Correlation with Complications – Exploring the Millimeter Threshold. DOI: https://doi.org/10.1186/s13019-025-03817-9
    9. European Society of Thoracic Surgeons. (2022). Conference proceedings and poster presentations.
    10. Interactive CardioVascular and Thoracic Surgery. (2021). Immune profiling after minimally invasive lobectomy. DOI: https://doi.org/10.1093/icvts/ivaa296
    11. Kulle, C. B., et al. (2021). Is Elective Cancer Surgery Feasible During the Lock-Down Period of the COVID-19 Pandemic? DOI: https://doi.org/10.1002/jso.26436
    12. Falay, O., et al. (2021). Prediction of Spread Through Air Spaces with Preoperative 18F-FDG PET/CT in Primary Lung Adenocarcinoma. DOI: https://doi.org/10.1097/MNM.0000000000001414
    13. İşcan, M., Yavuz, Ö. (2026). Uniportal Robotic-Assisted Thoracic Surgery for Anatomical Lung Resections. DOI: https://doi.org/10.20452/wiitm.2026.18021
    14. Current Thoracic Surgery. (2026). Accepted publications in thoracic surgery and bibliometric analysis.
    15. Scopus Database Metrics. (n.d.). Author citation indicators and publication statistics.
    16. Turkish Thoracic Society; Turkish Society of Thoracic Surgery; European Society of Thoracic Surgeons. (n.d.). Professional membership records.
    17. Top Teachers Awards. (n.d.). Excellence in Research Award recognition framework. https://topteachers.net/
    18. CTSNet. (2024–2025). Robotic thoracic surgery and port catheter publications.
    19. Academic Curriculum Documentation. (2026). Teaching activities, conference participation, and scholarly output.